OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 jul 2007 - 22:49
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces promising results for Locteron Phase IIa clinical study
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today positive initial results of the ongoing SELECT-1 Phase IIa study with its lead product Locteron™, a controlled release interferon alfa for the treatment of chronic hepatitis C (HCV). In the 12-week Phase IIa study, the combination of the highest dose of Locteron evaluated until now, and the antiviral drug ribavirin, achieved an early virologic response (EVR) in 100% of the hepatitis C patients treated. The study reported an overall strong antiviral response at twelve weeks and an adverse event profile that shows substantial tolerability improvement compared to other interferons, either on the market or in development. OctoPlus is co-developing Locteron with its partner Biolex Therapeutics.
Datum laatste update: 28 december 2025